(Q37827173)

23 August 2017

1 reference

title

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers (English)

1 reference

23 August 2017

1 reference

ChEBI release 2020-05-28

4

Sagar Lonial

1 reference

23 August 2017

6

Kenneth C Anderson

1 reference

23 August 2017

1

Paul G Richardson

1 reference

23 August 2017

3

Jacob P Laubach

1 reference

23 August 2017

5

Asher A Chanan-Khan

1 reference

23 August 2017

Constantine S Mitsiades

series ordinal

2

object named as

Constantine S Mitsiades

1 reference

23 August 2017

language of work or name

English

0 references

publication date

10 January 2011

1 reference

British Journal of Haematology

23 August 2017

published in

1 reference

23 August 2017

volume

152

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

367-379

1 reference

VAD-based regimens as primary treatment for multiple myeloma

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Heat shock protein 90: inhibitors in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Regulation of apoptosis by endoplasmic reticulum pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Regulation of apoptotic and inflammatory cell signaling in cerebral ischemia: the complex roles of heat shock protein 70

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

The Hsp90 chaperone complex as a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Autologous hematopoietic stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Molecular chaperones in the cytosol: from nascent chain to folded protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Heat shock protein 90 as a molecular target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Clinical and biological significance of HSP89 alpha in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Differential expression of 70-kDa heat shock-protein in human oral tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Antimyeloma activity of heat shock protein-90 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

21 January 2018

New drugs for myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Discovery of the heat shock response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

High constitutive expression of heat shock protein 90α in human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2010.08360.X

10.1111/J.1365-2141.2010.08360.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference